Info - Leica Biosystems

Quality ControlDifferences in tissue processing and technical procedures in the user’s laboratory may produce significant variability in results,necessitating regular performance of in-house controls in addition to the following procedures.Controls should be fresh autopsy/biopsy/surgical specimens, formalin-fixed, processed and paraffin wax-embedded as soon as possiblein the same manner as the patient sample(s).Positive Tissue ControlUsed to indicate correctly prepared tissues and proper staining techniques.One positive tissue control should be included for each set of test conditions in each staining run.A tissue with weak positive staining is more suitable than a tissue with strong positive staining for optimal quality control and to detectminor levels of reagent degradation. 2Recommended positive control tissue is tonsil.If the positive tissue control fails to demonstrate positive staining, results with the test specimens should be considered invalid.Negative Tissue ControlShould be examined after the positive tissue control to verify the specificity of the labeling of the target antigen by the primary antibody.Recommended negative control tissue is muscle.Alternatively, the variety of different cell types present in most tissue sections frequently offers negative control sites, but this should beverified by the user.Non-specific staining, if present, usually has a diffuse appearance. Sporadic staining of connective tissue may also be observed insections from excessively formalin-fixed tissues. Use intact cells for interpretation of staining results. Necrotic or degenerated cells oftenstain non-specifically. 3 False-positive results may be seen due to non-immunological binding of proteins or substrate reaction products.They may also be caused by endogenous enzymes such as pseudoperoxidase (erythrocytes), endogenous peroxidase(cytochrome C), or endogenous biotin (eg. liver, breast, brain, kidney) depending on the type of immunostain used. To differentiateendogenous enzyme activity or non-specific binding of enzymes from specific immunoreactivity, additional patient tissues may be stainedexclusively with substrate chromogen or enzyme complexes (avidin-biotin, streptavidin, labeled polymer) and substrate-chromogen,respectively. If specific staining occurs in the negative tissue control, results with the patient specimens should be considered invalid.Negative Reagent ControlUse a non-specific negative reagent control in place of the primary antibody with a section of each patient specimen to evaluatenon-specific staining and allow better interpretation of specific staining at the antigen site.Patient TissueExamine patient specimens stained with NCL-CD31-1A10 last. Positive staining intensity should be assessed within the context of anynon-specific background staining of the negative reagent control. As with any immunohistochemical test, a negative result means thatthe antigen was not detected, not that the antigen was absent in the cells/tissue assayed. If necessary, use a panel of antibodies toidentify false-negative reactions.Results ExpectedNormal TissuesClone 1A10 detected the CD31 antigen (PECAM-1) on the surface of endothelial cells in a variety of tissues (n=52). Some reactivity wasalso noted in platelets, monocytes, granulocytes and B cells.Abnormal TissuesClone 1A10 stained endothelial cells in a variety of benign and malignant tumors (n=96).NCL-CD31-1A10 is recommended for use in the assessment of vascular invasion in neoplastic tissues.General LimitationsImmunohistochemistry is a multistep diagnostic process that consists of specialized training in the selection of the appropriate reagents;tissue selection, fixation, and processing; preparation of the IHC slide; and interpretation of the staining results.Tissue staining is dependent on the handling and processing of the tissue prior to staining. Improper fixation, freezing, thawing, washing,drying, heating, sectioning or contamination with other tissues or fluids may produce artefacts, antibody trapping, or false negativeresults. Inconsistent results may be due to variations in fixation and embedding methods, or to inherent irregularities within the tissue. 4Excessive or incomplete counterstaining may compromise proper interpretation of results.The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls andshould be evaluated within the context of the patient’s clinical history and other diagnostic tests by a qualified pathologist.Antibodies from Leica Biosystems Newcastle Ltd are for use, as indicated, on either frozen or paraffin-embedded sections with specificfixation requirements. Unexpected antigen expression may occur, especially in neoplasms. The clinical interpretation of any stainedtissue section must include morphological analysis and the evaluation of appropriate controls.Bibliography - General1. National Committee for Clinical Laboratory Standards (NCCLS). Protection of laboratory workers from infectious diseases transmittedby blood and tissue; proposed guideline. Villanova, P.A. 1991; 7(9). Order code M29-P.2. Battifora H. Diagnostic uses of antibodies to keratins: a review and immunohistochemical comparison of seven monoclonal andthree polyclonal antibodies. Progress in Surgical Pathology. 6:1–15. eds. Fenoglio-Preiser C, Wolff CM, Rilke F. Field & Wood, Inc.,Philadelphia.3. Nadji M, Morales AR. Immunoperoxidase, part I: the techniques and pitfalls. Laboratory Medicine. 1983; 14:767.4. Omata M, Liew CT, Ashcavai M, Peters RL. Nonimmunologic binding of horseradish peroxidase to hepatitis B surface antigen: apossible source of error in immunohistochemistry. American Journal of Clinical Pathology. 1980; 73:626.5. Kostopoulos I, Barbanis S, Kalekou H, et al. Male breast carcinoma of the papillary solid variant with unique CD34 positivity. VirchowsArchiv. 2003; 443(4):591–593.NCL-CD31-1A10Page 3